Objective Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting side effect of some anti-cancer drugs. However, medical staff frequently encounter difficulties in ascertaining the severity of CIPN. We sought to develop a questionnaire in order to accurately assess CIPN. The validity of this questionnaire was compared with that of free-style interviews. Methods We developed the CIPN self-check sheet by analyzing existing self-assessment tools for CIPN and matching the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) grades. From August to December 2011, 77 cancer patients participated in this study. In order to evaluate the validity of the CIPN self-check sheet compared with a free-style interview assessment, the cross-classification and κ coefficients between the CTCAE grades from each assessment and those from a comprehensive assessment were analyzed. The comprehensive assessment utilized information obtained from the medical examination, free-style interview and CIPN self-check sheet. Results Upon completion of the study, 248 CIPN self-check sheets were collected (median number of sheets per patient, 3; range, 1-14). The cross-classification analysis illustrated that the CIPN self-check sheet successfully identified all grade 3 cases. The coefficient of the CIPN self-check sheet was significantly higher than that of the free-style interviews [κ values: 0.988 (p<0.01) and 0.501 (p<0.01) for the self-check sheet and interviews, respectively]. Conclusion The CIPN self-check sheet can be used to assess the severity of CIPN based on the CTCAE grade more accurately than free-style interviews.
Introduction
Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting side effect of some anti-cancer drugs. Currently, many commonly used chemotherapy drugs, including platinum drugs, taxanes, vinca alkaloids, thalidomide and bortezomib, are known to be capable of causing CIPN (1, 2) . The incidence of CIPN varies from 10% to 100% depending on the anticancer drug (3) . The symptoms of CIPN are occasionally observed over a period of months or years and can cause patients to experience frustration, depression and a loss of purpose due to physical limitations in engaging in enjoyable activities (4) . Moreover, patients may also abandon treatment with alternative chemotherapies due to a decline in their activities of daily living (ADL). CIPN is a crucial issue that should be seriously considered in the field of chemotherapy. Although previous studies have proposed preventative strategies for treating CIPN (5) (6) (7) (8) , the effects are not promising for every patient. Furthermore, no drugs reliably cure CIPN, and in order to prevent the progression of CIPN, the decision to reduce the dose of the causative drug and/or cease chemotherapy altogether must be made according to the severity of CIPN. With the exception of some chemotherapy drugs (9, 10) , dose reduction may be associated with impaired efficacy. The most impor- tant consideration in the management of CIPN is to accurately assess the severity of the neurological manifestations of the disease in order to make a timely decision regarding dose modification. CIPN generally presents with subjective symptoms, such as sensory disorders and neuropathic pain. Symptoms resulting from functional disturbances of sensory neurons include sensory dullness, dysfunction of temperature perception and other abnormal sensations, such as burning sensations or the feeling as if something is stuck on the body. In practice, medical staff frequently have trouble ascertaining the severity of these neurological manifestations due to the subjective nature of the symptoms, and the accuracy of assessments of CIPN depends on the quality of information provided by the patient to the medical staff. More specifically, the problem with CIPN assessment is that inexperienced examiners may underestimate the severity of the patient's neurological manifestations because sufficient information regarding the subjective neurological manifestations is not collected. The Common Terminology Criteria for Adverse Events (CTCAE) published by the National Cancer Institute (NCI) is widely used in the field of therapeutic oncology. Dose reduction and/or the cessation of chemotherapy according to the CTCAE grade is recommended in routine clinical practice as well as many clinical trials. With respect to toxicity grading, the inconsistency in findings between individual examiners is a problem (11) , and errors in grading may result from misunderstandings surrounding the definition of the CTCAE grade. This study therefore aimed to develop a patient self-report questionnaire that can be used to compensate for variability in assessments of CIPN by examiners in order to easily and accurately determine a patient's CTCAE grade. We further aimed to test the validity of our questionnaire compared with that of free-style interviews.
Materials and Methods

Patients
From August to December 2011, 77 cancer patients receiving chemotherapy at our hospital with drugs that could potentially induce CIPN participated in this study. The most frequent disease in this study was colon cancer (Table 1) , and the most frequently used drug was oxaliplatin ( Table 2) . No patients reported any signs of neuropathy prior to receiving chemotherapy.
Procedure
All of the patients provided their written informed consent. This study was conducted in accordance with the Declaration of Helsinki and approved by the Faculty of Medicine, Shimane University Institutional Review Board. We developed a patient self-report questionnaire referred to as the CIPN self-check sheet. All patients used the CIPN selfcheck sheet translated into Japanese. The original and Japanese versions of the CIPN self-check sheet were compared to ensure that each sentence had the proper meaning by a person bilingual in English and Japanese. On days when chemotherapy was administered, the patients completed the CIPN self-check sheet and subsequently underwent a medical examination and free-style interview performed by a physician and nurse, respectively. The cross-classification method was performed to evaluate the validity of the CIPN self-check sheet. The κ coefficient was determined using the SPSS 16.0 statistical software package (SPSS Inc., Chicago, USA), and differences were considered significant for p values of <0.05.
Development of the CIPN self-check sheet
Selection of questionnaire items
The CIPN self-check sheet comprises questions concerning the upper and lower limbs and self-care ADLs (Figure) . The quality of life questionnaire used to assess chemotherapy-induced peripheral neuropathy (QLQ-CIPN Figure. CIPN self-check sheet 20), which was developed based on interviews with health care professionals and patients, includes a question regarding "numbness" assessed on a sensory scale (12) . We selected "sensory dullness" instead of "numbness" as an indicator of a disturbance of sensation. Three daily activities, namely writing, buttoning clothes and walking, were selected to assess the severity of symptoms based on the CTCAE grade. The QLQ-CIPN20 contains "writing" as an item assessed on a motor scale (12) . A question concerning the difficulty of writing was adopted because writing is an activity related to aspects of shopping and finance, which are considered instrumental ADLs (13); a limitation in these ADLs is classified as grade 2 with respect to severity in the CTCAE. The Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT-GOG/ Ntx ) (14) and Patient Neurotoxicity Questionnaire (PNQ) (15) include questions regarding the inability to walk and button clothes, both of which are considered important activities of daily living. A severe limitation in these activities indicates interference with self-care ADLs (13), described as a grade 3 limitation in the CTCAE. The Numerical Rating Scale (NRS) was used to identify changes in the intensity of neuropathic pain, and a question as to whether the patients felt physically limited in taking care of their daily physical needs appeared as the final question on the CIPN self-check sheet in order to determine the degree of limitation in self-care ADLs.
Determination of the corresponding CTCAE grade In order to avoid misjudgments in the grade by the examiners, the following method was established to determine the corresponding CTCAE grade. In cases in which the patient displayed symptoms of only items A, B, C, G, H, I, L and/ or M (Figure) , without symptoms of items D, E, F, J and/or K, the CIPN was assessed as grade 1. If the patients experienced any of the issues listed in items D, E, F, J and/or K, without physical limitations in their daily physical needs, the CIPN was scored as grade 2. For example, cases in which the patient had difficulty buttoning their clothes but were able to get dressed by themselves or had difficulty walking but were able to get around inside their house were deemed as grade 2. Cases in which the patient felt physically limited in addressing their daily physical needs ("yes" in item N) due to the presence of neurological symptoms was assessed as grade 3. Grades 4 and 5 indicated extremely advanced cases, in which the patient was unable to fill out the questionnaire; therefore, grades 4 and 5 were not included in the CIPN self-check sheet. 
Evaluation of the validity of the CIPN self-check sheet
In each investigation, a comprehensive assessment of the CTCAE grade was conducted using information obtained from three sources: the medical examination, the free-style interview and the CIPN self-check sheet. The assessment of the CTCAE grade based on the CIPN self-check sheet was performed as described in Determination of the corresponding CTCAE grade. The CTCAE grade obtained from the free-style interview was determined by the nurse conducting the interview. In order to evaluate the validity of the CIPN self-check sheet compared with that of the free-style interview, the cross-classification and κ coefficients between the CTCAE grades from each assessment in addition to the comprehensive assessment were analyzed.
Results
Upon the completion of the study, 248 CIPN self-check sheets were completed. On average, each patient completed three (range, 1-14) CIPN self-check sheets. The free-style interviews were unable to capture grade 3 symptoms 10 out of 11 times due to insufficient data gathering. The CIPN self-check sheet successfully identified all grade 3 cases (Table 3). The CIPN self-check sheets exhibited a significantly higher κ coefficient (0.988; p<0.01) than the free-style interviews (0.501; p<0.01). Taken together, these data indicate that the CIPN self-check sheet can be used to assess CIPN more accurately than a free-style interview. The severity of CIPN determined based on the free-style interviews was underestimated in 32% of the patients (80/248 times) because the examiners were unable to ask precise questions related to the impact of a given symptom on the patient's ADLs. In addition, the severity of CIPN determined based on the freestyle interview was misjudged in 4% of cases (9/248 times) due to deficiencies in understanding the CTCAE grades. Only two cases resulted in an incorrect diagnosis using the CTCAE self-check sheet. In one of these cases, the patient was unable to explain his complicated sensory symptoms using solely the items listed on the CIPN self-check sheet. In the other case, the symptoms were caused by invasion of the tumor into the spinal cord. Of the five patients who scored 7 or higher in the hands or arms and feet or legs on the NRS pain assessment, none indicated physical limitations in meeting their daily physical needs ("No" in item N).
Discussion
Dose reduction and/or the cessation of chemotherapy is the standard of care for preventing CIPN progression based on the disease severity indicated by the CTCAE grade. Delays in modifying the dose can result in significant CIPN progression, thus leading to declines in ADLs. However, dose reduction may be associated with reduced treatment efficacy, and obtaining an accurate assessment of the CIPN severity is necessary in order to make a timely decision regarding dose modification. In practice, incorrect CTCAE grade assignments may result from the examiner's inability to assess CIPN. We therefore developed the CIPN self-check sheet in order to compensate for the varying ability of examiners to assess CIPN by analyzing existing selfassessment tools for CIPN and matching the NCI-CTCAE grades and subsequently tested the validity of this new CIPN self-check sheet. In this study, 73% of the patients (56 of 77 patients) suffered from CIPN, a sufficient incidence to warrant an evaluation of the validity of the CIPN self-check sheet. Consequently, our data revealed that the CIPN selfcheck sheet can be used to more accurately assess CIPN than a free-style interview.
The PNQ consists of questions regarding neurological manifestations in both the upper and lower limbs, such as the hands or feet and arms or legs (15) . CIPN symptoms occasionally appear simultaneously in both the hands and feet (16) ; however, the details of the neurological manifestations typically differ at each site. The use of questions allowing the upper and lower limbs to be assessed separately permits the examiner to ascertain which part of the body and type of neurological manifestation interfere with a patient's daily activities. The Japanese have a custom of sitting with their legs folded under the buttocks and fully understand the notion of having a foot "fall asleep," described as a feeling of loss of feeling and/or a prickly sensation. Given this custom, some Japanese people tend to interpret "numbness" as an uncomfortable but bearable pain, such as "tingling." We attempted to avoid such ambiguous expressions by using the term "sensory dullness" instead of "numbness" in the questionnaire. Consequently, no patients with a score of 7 or greater on the NRS pain assessment reported that they had experienced limitations in self-care ADLs; a score of 7 or greater on the NRS assessment is categorized as severe pain (17, 18) . Because each person possesses a different sensitivity for pain, the severity of neuropathic pain should be determined based on the degree of interference with ADLs caused by neuropathic pain.
Our findings, which demonstrate the superiority of the CIPN self-check sheet over free-style interviews in terms of validity, points to some possible causes for the inconsistencies observed in CIPN assessments. First, the open questions used in free-style interviews cannot be used to adequately identify subjective neuropathic symptoms, as some patients themselves do not recognize their neurological symptoms as being associated with CIPN. Specifically, a patient's CIPN symptoms may differ from what they imagined before receiving a diagnosis of CIPN. Many patients exhibiting the initial symptoms of CIPN feel as if something is stuck on the soles of their feet or report difficulties with temperature sensation in their hands and/or feet. Affected patients are typically only able to recognize their neurological manifestations as CIPN symptoms after being educated about CIPN. Education and training programs are therefore needed to improve knowledge and neurologic assessment skills (19) .The CIPN self-check sheet may help medical staff to educate patients about classic CIPN symptoms. Second, most medical staff are unable to allocate sufficient time for medical interviews during limited consultation hours. Patients may thus miss opportunities to report their symptoms, especially if he/ she is somewhat unwilling to confide in the appraiser. The use of self-entry questionnaires, such as the CIPN self-check sheet, allows the patient to explain their symptoms honestly without feeling rushed. Third, there is a lack of knowledge of CTCAE grading. In the CTCAE (ver. 4.0), the difference between grade 2 and grade 3 is based on the presence of complications with ADLs. Grade 2 is characterized by moderate symptoms that limit instrumental ADLs, such as shopping, doing laundry, managing finances and finding transportation, whereas grade 3 is defined as the presence of severe symptoms that limit self-care ADLs, such as getting in and out of bed, dressing, eating, getting around inside the house, bathing and using the toilet (13, 20) . Even in the final process to assess the severity of the patient's condition, the possibility remains that the examiner may misjudge the CTCAE grade if the definition of each grade is not precisely understood. The CIPN self-check sheet, which includes the corresponding CTCAE grades, may help examiners to properly assign grades.
One limitation of this study is that we did not compare the validity of the CIPN self-check sheet with that of existing patient self-report questionnaires. Such comparisons are needed to verify whether the CIPN self-check sheet contains sufficient questions to properly enable the examiner to identify CIPN symptoms compared with other questionnaires. The symptoms of CIPN are typically symmetrical and begin distally (21) , and the majority of all CIPN cases progress from the gradual onset of symptoms (22) . The CIPN selfcheck sheet is not a tool capable of determining whether neurological manifestations are caused by CIPN. Therefore, in cases in which the neurological symptoms display sudden onset in an asymmetrical manner, we suggest that examiners consider causes other than CIPN and conduct further examinations in order to determine the underlying etiology of the patient's neurological manifestations.
Conclusion
The CIPN self-check sheet can be used to assess the severity of CIPN based on the CTCAE grade more accurately than free-style interviews. This increase in accuracy may allow medical staff to better make decisions regarding dose reduction or the cessation of chemotherapy in a timely manner. Future studies should test the validity of the CIPN selfcheck sheet question items by assigning CTCAE grades to the question items in the PNQ and FACT-GOG/Ntx as well as the CIPN self-check sheet itself prior to administering the questionnaires. We plan to continuously revise the CIPN self-check sheet in order to reflect subsequent modifications in later versions of the CTCAE. These efforts are expect to result in more accurate assessments of CIPN and eliminate inconsistencies between individuals and institutions when used in routine practice or clinical studies. Moreover, accurate assessments of CIPN have the potential to prevent the progression of CIPN.
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